David Salzman Picture for Pharma Tech Outlook.jpg

David W Salzman, Ph.D.

Founder and CEO

As founder and CEO of sRNAlyics, David leads all of the science and technological development required for identifying small RNA diagnostics, targeted assay design, validation and subsequent product development. This includes: establishing a software suite to execute data processing and analysis, sample sourcing, and target selection. David also drives business development by facilitating patent protection on IP, forming strategic partnerships with key opinion leaders, universities, and outside institutions.

David brings over 14 years of research expertise and insight in microRNA and small RNA biology with an emphasis on biogenesis, activity, and detection. He also has experience in developing clinical/pre-clinincal biomarker, PK/PD, diagnostic assay development in his a previous role as a Scientist at Biogen, and postdoctoral fellow at the Yale School of Medicine. David earned his Ph.D. from the University of Connecticut in Molecular Biology and Biochemistry, and a B.S. from the University of Hartford in Environmental Science.

David served as the CSO of Mira Dx where he lead projects to identify, develop, and commercialize germline DNA biomarkers for radiation and immuno-oncology therapeutic treatment response, outcome, and toxicty across multiple cancer types.

View his publication record here